A new report from Allied Market Research, released in Portland, Oregon, on November 9, 2017, studies the global market for postmenopausal vaginal atrophy drugs. It includes forecasts through 2022.
Postmenopausal vaginal atrophy, or PVA, happens when the body makes less estrogen after menopause. Because estrogen drops, vaginal tissue becomes thinner and drier and loses elasticity. Estrogen can also fall for other reasons, such as perimenopause while breastfeeding, surgical menopause, pelvic radiation and chemotherapy.
Several forces push the market forward. They include helpful healthcare reforms and high unmet need in emerging economies. Doctors are also slowly moving from systemic estrogen treatments, such as gels and patches, toward therapies without estrogen. In addition, PVA is becoming more common.
Some factors hold growth back, though. Diagnosis rates stay low, while current treatments carry certain risks.
The report splits the market by therapy type and drug form. On the therapy side, estrogen-based drugs include Premarin, Vagifem, Estrace, Estring and Femring. Non-estrogen drugs include BZA/CE, Osphena and Vaginorm. By form, the study covers gels, creams, tablets, rings and patches. It then looks at four regions: North America, Europe, Asia-Pacific and LAMEA.
Key companies named in the study are Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Limited, and Allergan plc.
